3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
6
Head & Neck
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Carboplatin
544
Pemetrexed
394
pembrolizumab
373
Cisplatin
358
Paclitaxel
285
Docetaxel
240
Gemcitabine
168
Nivolumab
158
Erlotinib Hydrochloride
147
Bevacizumab
114
atezolizumab
104
osimertinib
99
durvalumab
92
Etoposide
90
Gefitinib
68
130-nm albumin-bound paclitaxel
65
Cetuximab
64
Ipilimumab
60
Drug Therapy
51
Topotecan
48
Injections
44
tislelizumab
41
Afatinib
41
Cyclophosphamide
39
Albumin-Bound Paclitaxel
37
Vinorelbine
36
Crizotinib
34
cemiplimab
31
icotinib
26
Radiotherapy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
bempegaldesleukin
×
Thoracic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03138889
2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2
Terminated
162 enrolled
21 charts